Drug intelligence / Profile preview

3D1002

Development stage: Phase 2
Lead developer: 3D Medicines
Modality: Small Molecules
Administration: Oral

Overview

3D1002 is a selective antagonist of the prostaglandin E2 receptor subtype 4 (EP4), also known as E-type prostanoid receptor 4. It is being developed primarily for the management of moderate to severe cancer pain. The drug has received IND approval from the NMPA and is currently in advanced clinical development, including Phase IIa/IIb trials evaluating its safety and efficacy both alone and in combination with oxycodone hydrochloride sustained-release tablets (OxyContin). The developer, 3D Medicines, focuses on innovative therapies for cancer patients[1][2][5].

Targets

PTGER4 (Prostaglandin E2 receptor EP4 subtype)

Beyond the preview

Go deeper on 3D1002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3D1002.

Explore the full profile